Menu Back toS32-The-Basics-of-Health-Technology-Assessment-From-Clinical-Trials-to-Pricing

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S32] The Basics of Health Technology Assessment - From Clinical Trials to Pricing -

Session Chair(s)

Shunya  Ikeda, PhD

Shunya Ikeda, PhD

  • Professor
  • International University of Health and Welfare., Japan
Followed by 2-years pilot program, HTA was newly introduced in Japan in 2018. However, the number of products evaluated in the pilot program was limited and few of employees of pharmaceutical and medical devices industries experienced actual HTA process. This session help participants understand the Japanese HTA system and think about what they need to prepare to address the requirements. The session includes the overview of basic knowledges and Japanese system of HTA by an academic expert and the review of the report of Pharmaceutical Manufacturers Association Task Force Team on the procedures of HTA. Also, experiences in HTA pilot program will be shared by each representative from pharmaceutical and medical device companies.


Ataru  Igarashi, PhD

HTA - To Do or Not to Do, That Is the Question

Ataru Igarashi, PhD

  • Associate Professor, Department of Drug Policy and Management
  • Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan
Toshihiko  Aranishi, PhD

Framework of Cost-Effectiveness Analysis

Toshihiko Aranishi, PhD

  • Research Scientist, Health Outcomes/Health Technology Assessment
  • Eli Lilly Japan K.K, Japan
Shinya  Ohno, MPH

The Case and Process of Pharmaceutical in Pilot Program of Cost Effectiveness Evaluation

Shinya Ohno, MPH

  • HTA Specialist
  • Chugai Pharmaceutical Co., Ltd, Japan
Miyoshi  Asaoka, MBA

Cost-Effectiveness of Transcatheter Aortic Valve Implantation in Japan: Experience From the Japanese Pilot Health Technology Assessment

Miyoshi Asaoka, MBA

  • Director, Health Economics & Patient Engagement, THV
  • Edwards Lifesciences Limited, Japan